THYMOGLOBULIN Canada

Rosa Shields: volunteer and athlete. Rosa received Thymoglobulin with a liver and kidney transplant 13 years ago. She volunteers to help transplant patients at her local hospital and raise awareness of organ donation. She has won numerous medals competing in the World and Canadian Transplant Games in bowling and track-and-field events.

THYMOGLOBULIN® anti-thymocyte globulin rabbit

LYMPHOGLOBULIN® anti-thymocyte globulin equine

THYMOGLOBULIN: GROWING, GLOBAL
Publications, ongoing clinical studies, and global expansion all contributed to the steady growth of Thymoglobulin in 2006 and pointed to more of the same in years to come. A world-class product for the treatment and prevention of acute rejection in kidney transplants in the United States, and with broader label indications in other jurisdictions, Thymoglobulin is now used in 55 countries. We received marketing approval in Mexico in 2006, began selling in Russia, and anticipate approvals in the United Kingdom and Japan in 2007. We are now selling Thymoglobulin direct in China, where our transplant sales force is the first established by Genzyme in that country. These efforts are all part of our strategy to expand geographic markets and convert distributorships to direct sales.

Global expansion is being enhanced by publications and ongoing clinical studies. In late 2006, the New England Journal of Medicine published results from a clinical trial of Thymoglobulin in kidney transplant induction therapy in comparison with basiliximab, the other most commonly used treatment. The data showed that treatment with Thymoglobulin resulted in a reduced risk of acute rejection and other adverse outcomes. Genzyme has taken steps to ensure the supply of Thymoglobulin by qualifying our Waterford, Ireland, plant for the finishing operation, and by preparations to enlarge our manufacturing plant in Lyon, France.

Thymoglobulin has encouraging potential beyond the transplantation market to treat immune diseases. Current studies are exploring its mechanism of action in order to understand its applicability to diseases including diabetes and myelodysplastic syndromes.

MOZOBIL FOR BONE MARROW TRANSPLANTATION
With the acquisition of AnorMED in November 2006, Genzyme acquired the late-stage product candidate Mozobil, which holds the promise of changing the standard of care for bone marrow transplants. Mozobil mobilizes stem cells, causing them to move rapidly out of the bone marrow and into the blood stream, thereby improving the opportunity for successful outcomes in patients already eligible for transplants and broadening the number of patients who become eligible.

Enrollment is complete in two international pivotal clinical trials of Mozobil, one in multiple myeloma and one in non-Hodgkin's lymphoma. We expect top-line data to be available in the first half of 2007. We plan to file for approval on a global basis - in the United States, Europe, and Canada in early 2008 and in South America later that year. Annually, there are approximately 55,000 bone marrow transplants worldwide. In addition to the clinical benefits of higher stem cell yields, Mozobil could help lower costs by reducing post-transplant hospitalization rates and associated procedures.